Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
If anyone has paywall access to the Times, perhaps you could confirm, but I think you'll find that the BBC and Times are reporting on the use of PCR testing which is being facilitated by Collinson on the Govt behalf at airports, however The Times continues with a mention of a rapid saliva test being trialled very soon...but with very little detail.
Collinson is not in competition to AVCT/ODX/GDR etc. They are a provider of services ......from their website "Create better experiences for your travelling customers with our proprietary travel benefit programmes, including world leader Priority Pass."
They must therefore be buying any products they are using or trialling from another supplier.
BBC now quoting £140 per test....Wow, now that's inflation for you. It was only £120 per person according to the Times earlier this morning. LOL.
If it's us then I'm sure we'll get an RNS to clarify and also to clarify the price. If t is another test then I'd expect/hope that Cytiva/Avacta would RNS something ASAP to counter ant detrimental reaction...even just for PR purposes. The best is always worth waiting for.
I’ve seen it posted elsewhere that I’d you place a fill or kill order at or within the market size (5k shares for AVCT) then the MMS are obliged to complete the trade or must move the prices...perhaps someone else could confirm
Remember the "report" button. It is the best solution for ridding the board of deliberately disruptive posts.
Failing that, remember the "filter" button as that is the second defence against deliberately disruptive nonsense.
It'll probably break £1.40 twice before it does so a third time as they might still need to flush out a few weak holders at the £1.40 bid first.....a few will have missed it earlier on. Then we'll hopefully shift on upwards.
@Investor2210, You ought to be okay. Lots of traders would have jumped out at £1.30-£1.40 to take their 10%...but savvy buyers will wait out the first hour before making their move to buy. Hopefully we should rise again very soon.
@Canute40...Agreed. David from Avacta was uber positive in his statement and when you consider how many negatives he spoke about at the start (in his first contribution), it definitely sounds like they have managed to do the high specificity that an antigen test requires. Good on him.
He even went on to try and explain why they had been talking about challenges....almost as if there was some pride in explaining how many challenges they have faced....just the sort of thing someone with a completed or near completed product might want to do.
Klaus from Cytiva seems to be suggesting/hinting that we need a combined antigen/antibody test...if i understood him correctly. Might be something that they are aiming for and obviously there Affimer tech would help with that.